| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -144.6 | -65.6 |
| Net income | -144.8 | -65.7 |
| EPS (diluted, $ a share) | $-0.66 | $-0.37 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: GPCR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Structure Therapeutics Inc.: key numbers
- Share price
- $18.57Close, Nov 16
- Market cap
- $3.99B
- Shares outstanding
- 214.77MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Structure Therapeutics Inc.
All →Structure Therapeutics Financial Results
Structure Therapeutics reported third quarter 2026 financial results and provided a corporate update on its oral small molecule obesity portfolio, including the enrollment of its Phase 3 ACCOMPLISH program for aleniglipron. The company ended the quarter with $1.2 billion in cash and investments, which is expected to fund operations through 2028. Topline data from the registrational Phase 3 trials are anticipated in the second half of 2028.
“With our Phase 3 ACCOMPLISH program underway, we are advancing aleniglipron toward potential registration while building a broader portfolio of differentiated oral small molecule treatments for chronic weight management.”
Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics
“We are also advancing our oral small molecule amylin portfolio by progressing the multiple ascending dose clinical trial of ACCG-2671, preparing to initiate a Phase 1 clinical trial of ACCG-3535 and exploring GLP-1 combination approaches.”
Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics